Volume 4.45 | Nov 19

Pulmonary Cell News 4.45 November 19, 2015
Pulmonary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PULCN on Twitter
Interleukin-4 and Interferon-γ Orchestrate an Epithelial Polarization in the Airways
Primary normal human bronchial epithelial cells (NHBEs) were exposed to interleukin-4 (IL-4), interferon-γ (IF-γ), or both and genome-wide transcriptome analysis was performed. The authors uncovered an antagonistic regulation pattern of IL-4 and IFN-γ in NHBEs, translating the T helper type 1 and 2 antagonism directly in epithelial gene regulation. [Mucosal Immunol] Abstract
Watch Now: Webinar on Gastrointestinal Organoids by Dr. Meritxell Huch
PUBLICATIONS (Ranked by impact factor of the journal)
Salidroside Protects against Bleomycin-Induced Pulmonary Fibrosis: Activation of Nrf2-Antioxidant Signaling, and Inhibition of NF-κB and TGF-β1/Smad-2/-3 Pathways
Investigators explored the therapeutic effects of salidroside on pulmonary fibrosis. Salidroside was capable of reversing the recombinant TGF-β1-induced epithelial-mesenchymal transition-like changes in alveolar epithelial cells in vitro. [Cell Stress Chaperones] Abstract

Role of Pro-inflammatory Cytokines in Radiation-Induced Genomic Instability in Human Bronchial Epithelial Cells
Scientists investigated whether IL-8 induction is part of a broader pro-inflammatory response produced by epithelial cells in response to damage, which influences genomic instability measured by increased micronuclei and DNA repair foci frequencies. [Radiat Res] Abstract

Nontypeable Haemophilus influenzae Exploits the Interaction between Protein-E and Vitronectin for the Adherence and Invasion to Bronchial Epithelial Cells
The authors hypothesized that protein-E, an outer membrane protein of nontypeable H. influenzae (NTHi), plays a role in this penetration into bronchial epithelial cells. NTHi strains invaded bronchial epithelial cells and the intracellular bacteria were localized in early endosomes. [BMC Microbiol] Full Article


Overexpression of Major CDKN3 Transcripts Is Associated with Poor Survival in Lung Adenocarcinoma
The authors analyzed cyclin-dependent kinase inhibitor 3 (CDKN3) expression and its association with patient survival in three cohorts of lung adenocarcinoma. CDKN3 transcripts were further analyzed in a panel of cell lines and lung adenocarcinoma tissues. [Br J Cancer] Abstract

miR-411 Contributes the Cell Proliferation of Lung Cancer by Targeting FOXO1
Scientists found miR-411 was overexpressed in lung cancer cells; overexpression of miR-411 promoted anchorage-dependent and anchorage-independent growths of lung cancer, while miR-411 knockdown reduced this effect. [Tumor Biol] Abstract

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
Researchers described the establishment and characterization of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant non-small cell lung cancer (NSCLC) cell lines and a pilot study on the effects of a combined MET and EGFR inhibitors treatment. [PLoS One] Full Article

Tangeretin Derivative, 5-Acetyloxy-6,7,8,4′-Tetramethoxyflavone Induces G2/M Arrest, Apoptosis and Autophagy in Human Non-Small Cell Lung Cancer Cells In Vitro and In Vivo
The authors investigated the anticancer effects of 5-acetyloxy-6,7,8,4′-tetramethoxyflavone on CL1-5 non-small cell lung cancer cells both in vitro and in vivo. [Cancer Biol Ther] Abstract

Digitoxin and Its Synthetic Analog MonoD Have Potent Antiproliferative Effects on Lung Cancer Cells and Potentiate the Effects of Hydroxyurea and Paclitaxel
Investigators evaluated the in vitro antiproliferative activity of the cardiac glycoside digitoxin and its synthetic analog MonoD on H460 lung cancer cells grown under different culture conditions. [Oncol Rep] Abstract

Air-Liquid Interface Culture for Respiratory Research: Watch Q&A Video
Novel Concepts in Airway Inflammation and Remodeling in Asthma
The authors highlight the gaps in our knowledge about the mechanisms underlying airway remodeling, the relationships between remodeling, inflammation and function, remodeling and clinical phenotypes, and the importance of utilizing innovative and realistic pre-clinical models to uncover effective, disease-modifying therapeutic strategies. [Eur Respir J] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (Nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Pharmaceuticals, Inc. announced the presentation of new analyses of OFEV for the treatment of IPF. [Press release from Boehringer Ingelheim Pharmaceuticals, Inc. discussing research presented at the Pulmonary Fibrosis Foundation’s PFF Summit 2015, Washington] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
Pfizer Reports Positive Topline Results from Phase III Trial Comparing XALKORI® (Crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Pfizer Inc. announced that PROFILE 1029, a Phase III study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI®, met its primary objective of significantly prolonging progression-free survival in previously untreated East Asian patients with ALK-positive advanced NSCLC when compared to a standard chemotherapy doublet. [Pfizer Inc.] Press Release

PTC Completes Enrollment of Phase III Clinical Trial of Translarna™ for Patients with Cystic Fibrosis
PTC Therapeutics, Inc. announced that it has completed enrollment of ACT CF, the company’s second Phase III clinical trial of Translarna™ for patients with nonsense mutation cystic fibrosis. [PTC Therapeutics, Inc.] Press Release

Lilly and Merck Expand Immuno-Oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
Eli Lilly and Company and Merck announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s ALIMTA® and Merck’s KEYTRUDA® in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer. [Eli Lilly and Company] Press Release

Nivolumab in Non-Small Cell Lung Cancer: Indication of Major Added Benefit for Under-75-Year-Olds
The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether nivolumab offers an added benefit over the appropriate comparator therapy in the treatment of non-small cell lung cancer. [Institute for Quality and Efficiency in Health Care] Press Release

Tagrisso™ (Osimertinib) (AZD9291) Approved by the US FDA as Treatment for Patients with EGFR T790M Mutation-Positive Metastatic Non-Small Cell Lung Cancer
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved TAGRISSO™ 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. [AstraZeneca] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Clinical Applications of Stem Cells
February 24-25, 2016
Singapore, Singapore

Visit our events page to see a complete list of events in the pulmonary cell community.
NEW Investigator – Cancer Biology (Wake Forest Baptist School of Medicine)

Postdoctoral Fellow – Cancer Biology (Cold Spring Harbor Laboratory)

Professorship – Respiratory Science (University of Cambridge)

Postdoctoral Positions – Fibrotic Remodeling of the Lung (University of Vermont)

Postdoctoral Positions – Cancer (University of Texas MD Anderson Cancer Center)

Post-Doctoral Fellow – Lung Microbiome Research and Asthma (University of Michigan)

PhD Studentships – Cancer Research (University of Cambridge)

Postdoctoral Position – Pulmonary Research (Helmholtz Association)

Postdoctoral Position – Lung Biology Research (University of Southern California)

Postdoctoral Fellowship – Developmental Cell Biology and Regenerative Medicine (University of California San Francisco)

Postdoctoral Researcher – Molecular Mechanisms of Pulmonary Diseases (Eastern Virginia Medical School)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pulmonary Cell News: Archives | Events | Contact Us